Wellington, 3 Feb (PL) The New Zealand Trade Commission today upheld the fine imposed on the pharmaceutical company Reckitt Benckiser, maker of Nurofen, a deceptive drug.
A court in the city of Auckland fined the company more than 785,000 $ for misleading consumers.
According to the Commission, Reckitt Benckiser admitted that between 2011 and 2015 he gave misleading information about the nature, characteristics and suitability of a range of Nurofen products.
The Nurofen line of pain relievers is marketed for migraines, back pain, menstrual disorders, and stress-induced headaches.
However, all were found to contain the same drug base, 342 milligrams of ibuprofen lysine.
The ruling follows an Australian court fined Reckitt Benckiser $ 4,400,000 in mid-December for misleading the consumer.
The company was found guilty of misinforming the consumer, assuring that certain Nurofen painkillers would relieve a specific pain.
